PankajBhargavaMD

PubMed

• MMP-9 deficiency confers resilience in Fibrodysplasia Ossificans Progressiva in a man and mice.
  Vitali Lounev, Jay C Groppe, Niambi Brewer, Kelly L Wentworth, Victoria Smith, Meiqi Xu, Lutz Schomburg, Pankaj Bhargava, Mona Al Mukaddam, Edward C Hsiao, Eileen M Sh...> ;Journal of Bone and Mineral Research. 2024 Feb 16
• 1 citations
  Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
  Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Kirsten Fischer, Anna-Mari...> ;Hemasphere. 2022 Jun 1
• 5 citations
  Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
  Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Kir...> ;Hemasphere. 2022 Apr 1
• 22 citations
  Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
  Manish A Shah, David Cunningham, Jean-Philippe Metges, Eric Van Cutsem, Zev Wainberg, Emon Elboudwarej, Kai-Wen Lin, Scott Turner, Marianna Zavodovskaya, David Inzunza...> ;Journal for Immunotherapy of Cancer. 2021 Dec 1
• 26 citations
  Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
  Manish A. Shah, György Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna C. Bendell, Dung Thai, Joyce He, Pankaj Bhargava, Jaffer A. ...> ;Journal of Clinical Oncology. 2021 Feb 12
• 13 citations
  Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
  Franck Morschhauser, Martin J. S. Dyer, Harriet S. Walter, Alexey V. Danilov, Loic Ysebaert, Daniel J. Hodson, Christopher Fegan, Simon Rule, John Radford, Guillaume C...> ;Leukemia. 2020 Dec 17
• 5 citations
  Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia
  Noriko Fukuhara, Tomohiro Kinoshita, Kazuhito Yamamoto, Hirokazu Nagai, Koji Izutsu, Go Yamamoto, Pankaj Bhargava, Nishan Rajakumaraswamy, Rita Humeniuk, Anita Mathias...> ;Japanese Journal of Clinical Oncology. 2020 Dec 16
• 1 citations
  No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
  Jacqueline C. Barrientos, Peter Hillmen, Gilles Salles, Jeff P. Sharman, Stephan Stilgenbauer, Oksana Gurtovaya, Guan Xing, Bianca Ruzicka, Pankaj Bhargava, Paolo Ghia...> ;Leukemia & Lymphoma. 2021 Mar 21
• 17 citations
  Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
  Johanna C. Bendell, Sunil Sharma, Manish R. Patel, Kevin S Windsor, Zev A. Wainberg, Michael S. Gordon, Jordan Berlin, Carrie Baker Brachmann, Marianna Zavodovskaya, J...> ;The Oncologist. 2020 Nov 1
• 18 citations
  Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
  Max J. Gordon, Julie Huang, Rebecca J. Chan, Pankaj Bhargava, Alexey V. Danilov> ;British Journal of Haematology. 2021 Feb 1
• 38 citations
  Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
  Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon Rule, Ebenezer A Kio, Lionel Karlin, Martin J. S. Dyer, Siddhartha Mitra, Ping Cheng Yi, Ri...> ;Clinical Cancer Research. 2020 Mar 10
• 47 citations
  Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, po...
  Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yeung-Chul Mun, Neil E. Kay, Tait D. Shanafelt, Kari G. Rabe, John C. Byrd, Asher Chanan-Khan, Richard...> ;The Lancet. Haematology. 2019 Jul 1
• 21 citations
  Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-base...
  Paul Ruff, David R. Ferry, Radek Lakomỳ, Jana Prausová, Guy van Hazel, Paulo M. Hoff, David Cunningham, Dirk Arnold, Hans J. Schmoll, Vladimir Moiseyenko, Joseph McKen...> ;European Journal of Cancer. 2015 Jan 1
• Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
  Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF> ;Eur. J. Cancer. 2013-09-01
• 38 citations
  Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
  Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas A. Abrams, Peter C. Enzinger, Nadine Jackson McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava...> ;The Oncologist. 2013 Apr 1
• 50 citations
  Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
  Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pank...> ;Clinical Cancer Research. 2013 Mar 15
• 192 citations
  Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
  Jennifer A. Chan, Keith Stuart, Craig C. Earle, Jeffrey W. Clark, Pankaj Bhargava, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Peter C. Enzinger, Jeffrey A. Meyerhardt...> ;Journal of Clinical Oncology. 2012 Aug 20
• 87 citations
  Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
  Dmitry Nosov, Brooke Esteves, Oleg Lipatov, Alexei A. Lyulko, A. A. Anischenko, Raju Titus Chacko, Dinesh C. Doval, Andrew Strahs, William Slichenmyer, Pankaj Bhargava> ;Journal of Clinical Oncology. 2012 May 10
• Multicenter phase Ib/II study of everolimus (RAD001) and tivozanib (AV-951) in patients with refractory, metastatic colorectal cancer.
  Wolpin BM, Ng K, Zhu AX, Abrams TA, Enzinger PC, McCleary N, Meyerhardt JA, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Elliott M, S...> ;J. Clin. Oncol.. 2012-02-01
• 76 citations
  Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedu...
  Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni va...> ;Clinical Cancer Research. 2011 Nov 15
• 82 citations
  A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
  Jennifer A. Chan, Lawrence S. Blaszkowsky, Peter C. Enzinger, David P. Ryan, Thomas A. Abrams, Andrew X. Zhu, Jennifer S. Temel, Deborah Schrag, Pankaj Bhargava, Jeffr...> ;Annals of Oncology. 2011 Jun 1
• Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asia...
  Mok T, Tan E, Park K, Jac J, Han M, Payumo FC, Credi M, McKee K, Cotreau MM, Bhargava P, Slichenmyer W> ;J. Clin. Oncol.. 2011-05-20
• Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).
  Kabbinavar FF, Srinivas S, Hauke RJ, Amato RJ, Esteves WB, Cotreau MM, Strahs AL, Bhargava P, Fishman MN> ;J. Clin. Oncol.. 2011-05-20
• Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).
  Nosov D, Bhargava P, Esteves WB, Strahs AL, Lipatov ON, Lyulko OO, Anischenko AO, Chacko RT, Doval D, Slichenmyer WJ> ;J. Clin. Oncol.. 2011-05-20
• Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients ...
  Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, Tan DS, Sun J, Jac J, Han M, Payumo FC, Credi M, McKee K, Cotreau MM, Bhargava P, Slichenmyer W> ;J. Clin. Oncol.. 2011-05-20
• Join now to see all